Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 23, 2025Scientific ReportsOpen Access

Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

GZGuihua ZhangSCShengya CaoCGChong Geng

Discussion

Loading...

Member takes

Overview

Single-cell and bulk transcriptomics highlights PRKD2's role in tumor stemness and axitinib sensitivity in multiple myeloma.

Key Points

  • Axitinib boosts apoptosis in PRKD2-overexpressing cells, suggesting therapeutic angles for intervention.
  • The study shows PRKD2 is linked to immune escape and clonal evolution, impacting multiple myeloma aggressiveness.
  • Bulk RNA-seq and single-cell transcriptomics reveal PRKD2's vital role in driving tumor stemness and progression.
  • Targeting PRKD2 may offer new strategies to combat high-risk multiple myeloma and improve patient outcomes.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68fa32a40df2e6cd2f7421b5https://doi.org/10.1038/s41598-025-20615-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell profiling uncovers PTPRG-driven stemness in malignant plasma cells and signatures of treatment failure in multiple myeloma2025
  2. 2Oncogenic ASPP2κ: A novel regulator of drug resistance and tumor progression in multiple myeloma2025
  3. 3Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma2026
  4. 4KPNA2 enhances autophagy through activation of the non-canonical NF-κB signaling pathway, thereby promoting the induction of bortezomib resistance in multiple myeloma2025
  5. 5DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma2026